newsfilter
← Latest News
GlobeNewswire·

Biomea Fusion Reports Second Quarter 2026 Financial Results and Corporate Highlights

Enrollment ongoing for the Phase II COVALENT-211 clinical trial in patients with insulin deficiency in Type 2 diabetes ("T2D"); data expected in the first quarter of 2027Enrollment also ongoing for the Phase II